WHAT IS CLAIMED IS:

1. A method for increasing hybridoma fusion efficiency, comprising synchronizing the fusing partner myeloma cells.

2. The method of claim 1, wherein the myeloma cells are selected from the group consisting of: P3-X63/Ag8, X63-Ag8.653, NS1/1.Ag 4 1, Sp210-Ag14, FO, MPC-11, MPC11-X45-GTG 1.7 and S194/5XX0 Bul.

3. The method of claim 1, wherein the synchronization is achieved through serum starvation.

4. A method for increasing hybridoma fusion efficiency, comprising synchronizing the fusing partner antibody-producing B cells.

5. The method of claim 4, wherein the antibody-producing B cells are obtained from spleens, tonsils or lymph nodes, or from a peripheral blood sample.

6. The method of claim 4, wherein the synchronization is achieved through serum starvation.

What is claimed is:

1. A method for increasing hybridoma fusion efficiency comprising synchronizing a cell selected from the group consisting of: i) a fusing partner myeloma cell; and ii) a fusing partner antibody producing B cell; wherein the synchronization is achieved by serum starvation followed by restoration of normal growth media.

2. The method of claim 1 wherein said myeloma cells are selected from the group consisting of P3-X63/Ag8, X63-Ag8.653, NS1/1.Ag 4 1, SP210-Ag14, FO, NSO/U, MPC-11, MPC11-X45-GTG 1.7 and S194/5XXO Bul.

3. The method of claim 1 wherein said antibody producing B-cell is obtained from a source selected from the group consisting of spleens, tonsils, lymph nodes, and peripheral blood.